24E79135-8904-49F9-A748-AC059F325450
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.268068331143231
- age_years
- 71
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.563
- E2F_TARGETS+0.524
- DNA_REPAIR+0.505
- G2M_CHECKPOINT+0.478
- INTERFERON_ALPHA_RESPONSE+0.461
- OXIDATIVE_PHOSPHORYLATION+0.449
- INTERFERON_GAMMA_RESPONSE+0.409
- NOTCH_SIGNALING+0.407
- PROTEIN_SECRETION+0.380
- UNFOLDED_PROTEIN_RESPONSE+0.356
Top 10 suppressed
- KRAS_SIGNALING_DN-0.427
- MYOGENESIS-0.196
- SPERMATOGENESIS-0.183
- APICAL_SURFACE-0.117
- HEDGEHOG_SIGNALING-0.098
- APICAL_JUNCTION-0.096
- ESTROGEN_RESPONSE_EARLY-0.004
- COAGULATION+0.029
- CHOLESTEROL_HOMEOSTASIS+0.033
- ESTROGEN_RESPONSE_LATE+0.063
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 812834CD-DA8F-4C0C-A49E-31D4A882D0E0 | — | — | 0.956 |
| 2 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.943 |
| 3 | C14BEAAE-A766-4ADE-A9B4-674D8717591F | — | — | 0.939 |
| 4 | 40CDF034-0EBC-42A1-BBD8-492C1494086E | — | — | 0.935 |
| 5 | 6B8CAF74-45C6-4C20-8126-A99F73346198 | — | — | 0.935 |
| 6 | 68B73B22-487B-43D8-9B68-06AD1022F46D | — | — | 0.935 |
| 7 | 93A7AA5D-FA07-470A-9FD3-306EA577D3C4 | — | — | 0.931 |
| 8 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.928 |
| 9 | EB8F7B74-694A-4F9F-9C0B-F04006033CA4 | — | — | 0.926 |
| 10 | SRR934929 | — | — | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.563 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.524 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.505 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.478 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.461 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.449 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.409 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.407 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.356 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.346 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.339 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.329 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.326 | Idelalisib | — uncovered |
| APOPTOSIS | 0.323 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.323 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.317 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.317 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.308 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.286 | Idelalisib | — uncovered |